眼科指南

订阅

MedSci主页 / 所有栏目 / 眼科指南

2018 临床实践指南：玻璃体内注射抗血管内皮生长因子药物治疗眼部血管疾病

2018-04-30 国外眼科专家协作组（统称） J Ophthalmic Vis Res. 2018 Apr-Jun;13(2):158-169.

玻璃体内注射抗血管内皮生长因子眼部血管疾病

本文主要针对玻璃体内注射抗血管内皮生长因子药物特别是贝伐单抗治疗眼部血管疾病，包括糖尿病性黄斑水肿，年龄相关性黄斑变性，近视脉络膜新生血管，视网膜静脉阻塞以及中心浆液性脉络膜视网膜病变的相关内容提出指导建议，全文共涉及21个临床问题，最终形成56条推荐意见。

中文标题：

2018 临床实践指南：玻璃体内注射抗血管内皮生长因子药物治疗眼部血管疾病

英文标题：

Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline.

发布机构：

国外眼科专家协作组（统称）

发布日期：

2018-04-30

简要介绍：

本文主要针对玻璃体内注射抗血管内皮生长因子药物特别是贝伐单抗治疗眼部血管疾病，包括糖尿病性黄斑水肿，年龄相关性黄斑变性，近视脉络膜新生血管，视网膜静脉阻塞以及中心浆液性脉络膜视网膜病变的相关内容提出指导建议，全文共涉及21个临床问题，最终形成56条推荐意见。

拓展指南：与玻璃体相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 临床实践指南：玻璃体内注射抗血管内皮生长因子药物治疗眼部血管疾病)] GetToolGuiderByIdResponse(projectId=1, id=0100e1c00158810b, title=2018 临床实践指南：玻璃体内注射抗血管内皮生长因子药物治疗眼部血管疾病, enTitle=Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline., guiderFrom=J Ophthalmic Vis Res. 2018 Apr-Jun;13(2):158-169., authorId=null, author=, summary=本文主要针对玻璃体内注射抗血管内皮生长因子药物特别是贝伐单抗治疗眼部血管疾病，包括糖尿病性黄斑水肿，年龄相关性黄斑变性，近视脉络膜新生血管，视网膜静脉阻塞以及中心浆液性脉络膜视网膜病变的相关内容提出指导建议，全文共涉及21个临床问题，最终形成56条推荐意见。 , cover=, journalId=null, articlesId=null, associationId=959, associationName=国外眼科专家协作组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Mon Apr 30 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>本文主要针对玻璃体内注射抗血管内皮生长因子药物特别是贝伐单抗治疗眼部血管疾病，包括糖尿病性黄斑水肿，年龄相关性黄斑变性，近视脉络膜新生血管，视网膜静脉阻塞以及中心浆液性脉络膜视网膜病变的相关内容提出指导建议，全文共涉及21个临床问题，最终形成56条推荐意见。</div> <div><br> </div>拓展指南：<strong>与<font color=red>玻璃体</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=0100e1c00158810b" title="2018 临床实践指南：玻璃体内注射抗血管内皮生长因子药物治疗眼部血管疾病" target=_blank>2018 临床实践指南：玻璃体内注射抗血管内皮生长因子药物治疗眼部血管疾病</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=724321c001552199" title="2018 EURETINA专家共识建议：玻璃体内注射（更新版）" target=_blank>2018 EURETINA专家共识建议：玻璃体内注射（更新版）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=971bd1c001315562" title="2015 NICE技术评估指南：玻璃体腔内注射地塞米松治疗糖尿病性黄斑水肿（TA349）" target=_blank>2015 NICE技术评估指南：玻璃体腔内注射地塞米松治疗糖尿病性黄斑水肿（TA349）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=30e941c0009968e4" title="2013 AAO 玻璃体后脱离，视网膜裂孔并格子样变性管理指南" target=_blank>2013 AAO 玻璃体后脱离，视网膜裂孔并格子样变性管理指南</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E7%8E%BB%E7%92%83%E4%BD%93" target=_blank>有关玻璃体更多指南</a></ul>, tagList=[TagDto(tagId=51623, tagName=玻璃体内注射), TagDto(tagId=60377, tagName=抗血管内皮生长因子), TagDto(tagId=74445, tagName=眼部血管疾病)], categoryList=[CategoryDto(categoryId=32, categoryName=眼科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7564, appHits=327, showAppHits=0, pcHits=5681, showPcHits=2684, likes=128, shares=8, comments=3, approvalStatus=1, publishedTime=Sun May 06 21:40:03 CST 2018, publishedTimeString=2018-04-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun May 06 21:40:03 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 10:30:33 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 临床实践指南：玻璃体内注射抗血管内皮生长因子药物治疗眼部血管疾病)])
2018 临床实践指南：玻璃体内注射抗血管内皮生长因子药物治疗眼部血管疾病
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=315606, encodeId=d31d31560658, content=学习了谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed May 16 08:26:05 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313802, encodeId=6d51313802be, content=有效.值得推广--, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Thu May 10 11:41:45 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312636, encodeId=6269312636c1, content=本文主要针对玻璃体内注射抗血管内皮生长因子药物特别是贝伐单抗治疗眼部血管疾病.包括糖尿病性黄斑水肿.年龄相关性黄斑变性.近视脉络膜新生血管.视网膜静脉阻塞以及中心浆液性脉络膜视网膜病变的相关内容提出指导建议.全文共涉及21个临床问题.最终形成56条推荐意见., beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun May 06 22:51:20 CST 2018, time=2018-05-06, status=1, ipAttribution=)]
    2018-05-16 半夏微凉

    学习了谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=315606, encodeId=d31d31560658, content=学习了谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed May 16 08:26:05 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313802, encodeId=6d51313802be, content=有效.值得推广--, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Thu May 10 11:41:45 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312636, encodeId=6269312636c1, content=本文主要针对玻璃体内注射抗血管内皮生长因子药物特别是贝伐单抗治疗眼部血管疾病.包括糖尿病性黄斑水肿.年龄相关性黄斑变性.近视脉络膜新生血管.视网膜静脉阻塞以及中心浆液性脉络膜视网膜病变的相关内容提出指导建议.全文共涉及21个临床问题.最终形成56条推荐意见., beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun May 06 22:51:20 CST 2018, time=2018-05-06, status=1, ipAttribution=)]
    2018-05-10 祝您健康

    有效.值得推广--

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=315606, encodeId=d31d31560658, content=学习了谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed May 16 08:26:05 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313802, encodeId=6d51313802be, content=有效.值得推广--, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Thu May 10 11:41:45 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312636, encodeId=6269312636c1, content=本文主要针对玻璃体内注射抗血管内皮生长因子药物特别是贝伐单抗治疗眼部血管疾病.包括糖尿病性黄斑水肿.年龄相关性黄斑变性.近视脉络膜新生血管.视网膜静脉阻塞以及中心浆液性脉络膜视网膜病变的相关内容提出指导建议.全文共涉及21个临床问题.最终形成56条推荐意见., beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Sun May 06 22:51:20 CST 2018, time=2018-05-06, status=1, ipAttribution=)]
    2018-05-06 有备才能无患

    本文主要针对玻璃体内注射抗血管内皮生长因子药物特别是贝伐单抗治疗眼部血管疾病.包括糖尿病性黄斑水肿.年龄相关性黄斑变性.近视脉络膜新生血管.视网膜静脉阻塞以及中心浆液性脉络膜视网膜病变的相关内容提出指导建议.全文共涉及21个临床问题.最终形成56条推荐意见.

    0

相关指南

2018 EURETINA专家共识建议：玻璃体内注射（更新版）

欧洲视网膜专家学会(EURETINA,European Society of Retina Specialists) · 2018-02-01